Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02898753 · ClinicalTrials.gov registry record · Phase 1
VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease
A Phase 1 study, sponsored by Valerion Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02898753 is a Phase 1 study that was terminated before completion, run by Valerion Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT02898753, a Phase 1 study, was terminated before completion, sponsored by Valerion Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This Phase I/II open-label, randomized, dose-escalation study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VAL-1221 versus Myozyme®/Lumizyme® in participants with late-onset glycogen storage disease-II (GSD-II) (Pompe disease)
Interventions
- DRUG VAL-1221
- DRUG RhGAA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-06-21 |
| Est. Completion | 2020-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02898753
The ClinicalTrials.gov registry entry for NCT02898753 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valerion Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VAL-1221 is the first listed.
NCT02898753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02898753 about?
NCT02898753 is a clinical study titled "VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease". This Phase I/II open-label, randomized, dose-escalation study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VAL-1221 versus Myozyme®/Lumizyme® in participants with late-onset glycogen storage disease-II (GSD-II) (Pompe disease)
What is the current status of trial NCT02898753?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-06-21. Estimated completion is 2020-03-25.
What interventions are being tested in trial NCT02898753?
The interventions under investigation include: VAL-1221 (DRUG), RhGAA (DRUG).
Who is sponsoring clinical trial NCT02898753?
This trial is sponsored by Valerion Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.